"Gout Suppressants" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that increase uric acid excretion by the kidney (URICOSURIC AGENTS), decrease uric acid production (antihyperuricemics), or alleviate the pain and inflammation of acute attacks of gout.
| Descriptor ID |
D006074
|
| MeSH Number(s) |
D27.505.954.329.337
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Gout Suppressants".
Below are MeSH descriptors whose meaning is more specific than "Gout Suppressants".
This graph shows the total number of publications written about "Gout Suppressants" by people in this website by year, and whether "Gout Suppressants" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 2 | 3 |
| 2011 | 5 | 1 | 6 |
| 2012 | 4 | 1 | 5 |
| 2013 | 2 | 2 | 4 |
| 2014 | 2 | 0 | 2 |
| 2015 | 2 | 1 | 3 |
| 2016 | 2 | 2 | 4 |
| 2017 | 6 | 2 | 8 |
| 2018 | 2 | 3 | 5 |
| 2019 | 3 | 0 | 3 |
| 2020 | 3 | 4 | 7 |
| 2021 | 0 | 5 | 5 |
| 2022 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gout Suppressants" by people in Profiles.
-
Allopurinol Initiation and All-Cause Mortality Among Patients With Gout and Concurrent Chronic Kidney Disease : A Population-Based Cohort Study. Ann Intern Med. 2022 04; 175(4):461-470.
-
SToRytelliing to Improve Disease outcomes in Gout (STRIDE-GO) in African American veterans with gout: a trial study protocol. Trials. 2021 Dec 04; 22(1):879.
-
Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group. Semin Arthritis Rheum. 2021 12; 51(6):1378-1385.
-
SToRytelling to Improve Disease outcomes in Gout (STRIDE-GO): a multicenter, randomized controlled trial in African American veterans with gout. BMC Med. 2021 11 09; 19(1):265.
-
Cardiovascular safety of febuxostat. Lancet. 2021 09 11; 398(10304):955.
-
How do dietary interventions affect serum urate and gout? Nat Rev Rheumatol. 2021 04; 17(4):191-192.
-
Shared decision-making in gout treatment: a national study of rheumatology provider opinion and practice. Clin Rheumatol. 2021 Feb; 40(2):693-700.
-
Response to: 'Cutaneous adverse events with febuxostat after previous reactions to allopurinol: comment on the artcile by Singh and Clevland' by Quills et al. Ann Rheum Dis. 2022 07; 81(7):e125.
-
Response to: 'Correspondence to "Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data' by Ma et al. Ann Rheum Dis. 2022 06; 81(6):e108.
-
Response to: 'Confunding by indication and ethnicity difference? Comment on 'Hypersensitivity reactions with allopurinol and febuxostat: a study using the Medicare claims data'' by Hsu et al. Ann Rheum Dis. 2022 07; 81(7):e123.